MYELOFIBROSIS
Clinical trials for MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for myelofibrosis patients who Can't take standard treatments
Disease control Not yet recruitingThis study tests a combination of two drugs, pacritinib and selinexor, in people with myelofibrosis who have not had prior JAK inhibitor therapy and have low red blood cells (anemia) and low platelets (thrombocytopenia). The goal is to see if the combination can shrink an enlarge…
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated May 26, 2026 04:54 UTC
-
Which drug wins for myelofibrosis? new trial pits momelotinib against ruxolitinib
Disease control Not yet recruitingThis study tests two FDA-approved drugs, momelotinib and ruxolitinib, in people with myelofibrosis who also have low blood cell counts. The main goal is to see which drug works better at shrinking an enlarged spleen and reducing the need for blood transfusions. About 268 particip…
Matched conditions: MYELOFIBROSIS
Phase: PHASE4 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 26, 2026 04:50 UTC
-
New combo therapy aims to shrink enlarged spleens in hard-to-treat blood cancer
Disease control Not yet recruitingThis study tests whether adding bomedemstat to the standard drug momelotinib can help people with myelofibrosis, a type of blood cancer. It is for patients whose spleen is still enlarged or who have low blood counts despite taking momelotinib alone. About 40 adults will take both…
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: United Lincolnshire Hospitals NHS Trust • Aim: Disease control
Last updated May 26, 2026 04:46 UTC
-
New combo therapy aims to tame bone marrow cancer
Disease control Not yet recruitingThis early-phase study tests whether adding the drug ropeginterferon alfa-2b to the standard treatment ruxolitinib is safe for people with myelofibrosis, a type of bone marrow cancer. About 15 adults already on a stable dose of ruxolitinib will receive the added drug. The main go…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
New hope for myelofibrosis patients: experimental pill targets enlarged spleens
Disease control Not yet recruitingThis study tests an experimental drug called TQ05105 in 51 adults with intermediate or high-risk myelofibrosis, a rare bone marrow cancer. The drug is given to patients whose disease has not responded to or has returned after standard JAK inhibitor therapy. The main goal is to se…
Matched conditions: MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 04:34 UTC
-
New drug rebecsinib tested for tough-to-treat blood cancers
Disease control Not yet recruitingThis early-stage study tests a new drug called rebecsinib in 28 people with secondary acute myeloid leukemia (sAML) that has come back or not responded to treatment, or with higher-risk myelofibrosis. The goal is to find the safest and most effective dose by giving the drug as an…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Aspera Biomedicines, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC